|
|
|
|
LEADER |
02636 am a22004693u 4500 |
001 |
108567 |
042 |
|
|
|a dc
|
100 |
1 |
0 |
|a Wein, Marc N.
|e author
|
100 |
1 |
0 |
|a Massachusetts Institute of Technology. Institute for Medical Engineering & Science
|e contributor
|
100 |
1 |
0 |
|a Xavier, Ramnik Joseph
|e contributor
|
700 |
1 |
0 |
|a Liang, Yanke
|e author
|
700 |
1 |
0 |
|a Goransson, Olga
|e author
|
700 |
1 |
0 |
|a Sundberg, Thomas B.
|e author
|
700 |
1 |
0 |
|a Wang, Jinhua
|e author
|
700 |
1 |
0 |
|a Williams, Elizabeth A.
|e author
|
700 |
1 |
0 |
|a O'Meara, Maureen J.
|e author
|
700 |
1 |
0 |
|a Govea, Nicolas
|e author
|
700 |
1 |
0 |
|a Beqo, Belinda
|e author
|
700 |
1 |
0 |
|a Nishimori, Shigeki
|e author
|
700 |
1 |
0 |
|a Nagano, Kenichi
|e author
|
700 |
1 |
0 |
|a Brooks, Daniel J.
|e author
|
700 |
1 |
0 |
|a Martins, Janaina S.
|e author
|
700 |
1 |
0 |
|a Corbin, Braden
|e author
|
700 |
1 |
0 |
|a Anselmo, Anthony
|e author
|
700 |
1 |
0 |
|a Sadreyev, Ruslan
|e author
|
700 |
1 |
0 |
|a Wu, Joy Y.
|e author
|
700 |
1 |
0 |
|a Sakamoto, Kei
|e author
|
700 |
1 |
0 |
|a Foretz, Marc
|e author
|
700 |
1 |
0 |
|a Baron, Roland
|e author
|
700 |
1 |
0 |
|a Bouxsein, Mary L.
|e author
|
700 |
1 |
0 |
|a Gardella, Thomas J.
|e author
|
700 |
1 |
0 |
|a Divieti-Pajevic, Paola
|e author
|
700 |
1 |
0 |
|a Gray, Nathanael S.
|e author
|
700 |
1 |
0 |
|a Kronenberg, Henry M.
|e author
|
700 |
1 |
0 |
|a Xavier, Ramnik Joseph
|e author
|
245 |
0 |
0 |
|a SIKs control osteocyte responses to parathyroid hormone
|
260 |
|
|
|b Nature Publishing Group,
|c 2017-05-02T13:52:13Z.
|
856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/108567
|
520 |
|
|
|a Parathyroid hormone (PTH) activates receptors on osteocytes to orchestrate bone formation and resorption. Here we show that PTH inhibition of SOST (sclerostin), a WNT antagonist, requires HDAC4 and HDAC5, whereas PTH stimulation of RANKL, a stimulator of bone resorption, requires CRTC2. Salt inducible kinases (SIKs) control subcellular localization of HDAC4/5 and CRTC2. PTH regulates both HDAC4/5 and CRTC2 localization via phosphorylation and inhibition of SIK2. Like PTH, new small molecule SIK inhibitors cause decreased phosphorylation and increased nuclear translocation of HDAC4/5 and CRTC2. SIK inhibition mimics many of the effects of PTH in osteocytes as assessed by RNA-seq in cultured osteocytes and following in vivo administration. Once daily treatment with the small molecule SIK inhibitor YKL-05-099 increases bone formation and bone mass. Therefore, a major arm of PTH signalling in osteocytes involves SIK inhibition, and small molecule SIK inhibitors may be applied therapeutically to mimic skeletal effects of PTH.
|
546 |
|
|
|a en_US
|
655 |
7 |
|
|a Article
|
773 |
|
|
|t Nature Communications
|